Skip to content

Search

Showing results for "early life"

The effectiveness of education and lived experience resources in reducing stigma towards young people at-risk of psychosis

This study aimed to evaluate and compare the effectiveness of two brief written anti-stigma resources.

What is triggering immune reactions in people with MS?

Multiple sclerosis (MS) is a condition where a person's immune system attacks the brain and spinal cord.

Pertussis (whooping cough) studies

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au The PRIME Study The

Generation Australia

A unique national platform delivering faster research at scale to improve the health, wellbeing and equity of children and their parents across Australia

International Clinical Trials Day 2026

To celebrate International Clinical Trials Day, we are highlighting some of the current trials underway at the Children's Diabetes Centre at the Kids Research Institute Australia and Perth Children's Hospital and thanking all the diabetes community who have said yes to diabetes research.

PACT training

Find out more about Paediatric Autism Communication Therapy training for allied health and autism professionals at CliniKids.

Let's play!

This is the start of our CliniKids blog series about play. In this blog, Speech Pathology Clinical Lead Aria May, explains why play is so important for autistic children.

Following your child's interest

In this blog, Senior Speech Pathologist Sally Grauaug and Speech Pathology Clinical Lead Aria May share tips on following your child's interest.

Acceptability of OP/Na swabbing for SARS-CoV-2: a prospective observational cohort surveillance study in Western Australian schools

When the COVID-19 pandemic was declared, Governments responded with lockdown and isolation measures to combat viral spread, including the closure of many schools. More than a year later, widespread screening for SARS-CoV-2 is critical to allow schools and other institutions to remain open.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.